Cargando…

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial

Tafenoquine is a novel 8-aminoquinoline antimalarial drug recently approved by the U.S. Food and Drug Administration (FDA) for the radical cure of acute Plasmodium vivax malaria, which is the first new treatment in almost 60 years. A population pharmacokinetic (POP PK) analysis was conducted with ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakkar, Nilay, Green, Justin A., Koh, Gavin C. K. W., Duparc, Stephan, Tenero, David, Goyal, Navin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201082/ https://www.ncbi.nlm.nih.gov/pubmed/30201820 http://dx.doi.org/10.1128/AAC.00711-18

Ejemplares similares

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects
por: Green, Justin A., et al.
Publicado: (2016)

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
por: Sinxadi, Phumla, et al.
Publicado: (2020)

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping
por: Beck, Hans-Peter, et al.
Publicado: (2016)

An Efficient and Sustainable Synthesis of the Antimalarial Drug Tafenoquine
por: Kavthe, Rahul D., et al.
Publicado: (2022)

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
por: McCarthy, James S., et al.
Publicado: (2016)

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
por: St Jean, Pamela L., et al.
Publicado: (2020)

In Vitro Antimalarial Activity of Inhibitors of the Human GTPase Rac1
por: Parapini, Silvia, et al.
Publicado: (2022)

Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review
por: Duparc, Stephan, et al.
Publicado: (2020)

KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
por: Kuhen, Kelli L., et al.
Publicado: (2014)

Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects
por: Green, Justin A, et al.
Publicado: (2014)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial
por: St Jean, Pamela L., et al.
Publicado: (2016)

Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species
por: Ong, Voon, et al.
Publicado: (2017)

Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers
por: Ackert, Jessica, et al.
Publicado: (2019)

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2023)

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1
por: Park, A. Young J., et al.
Publicado: (2022)

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum
por: Barber, Bridget E, et al.
Publicado: (2023)

Quantification of Tafenoquine and 5,6-Orthoquinone Tafenoquine by UHPLC-MS/MS in Blood, Plasma, and Urine, and Application to a Pharmacokinetic Study
por: Birrell, Geoffrey W., et al.
Publicado: (2022)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
por: Zhang, Cindy X., et al.
Publicado: (2022)

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
por: Francis, Jose, et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B
por: Guptill, J. T., et al.
Publicado: (2021)

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
por: Llanos-Cuentas, A., et al.
Publicado: (2019)

Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206
por: Bruss, Jon, et al.
Publicado: (2021)

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
por: Alghamdi, Wael A., et al.
Publicado: (2019)

Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats
por: Verschraagen, M, et al.
Publicado: (2004)

Photodynamic therapy effect of m-THPC (Foscan®) in vivo: correlation with pharmacokinetics
por: Jones, H J, et al.
Publicado: (2003)

Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats
por: Ireson, C R, et al.
Publicado: (2004)

Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents
por: Ireson, C R, et al.
Publicado: (2004)

Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
por: Duthaler, Urs, et al.
Publicado: (2016)

Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
por: Lakshminarayana, Suresh B., et al.
Publicado: (2015)

Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria
por: Lacerda, M.V.G., et al.
Publicado: (2019)

A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
por: Leong, F. Joel, et al.
Publicado: (2014)

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
por: Hodges, Michael R., et al.
Publicado: (2023)

Tafenoquine succinate for malaria prevention
Publicado: (2019)

Tafenoquine: a toxicity overview
por: Chu, Cindy S., et al.
Publicado: (2021)

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae
por: Ji, Xi-wei, et al.
Publicado: (2020)

Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene
por: Sale, S, et al.
Publicado: (2004)

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study
por: Sutanto, Inge, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t323otir4r52pnk9pidhv6noim